This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Abiomed Crecimiento futuro

Future controles de criterios 1/6

Información clave

-2.5%

Tasa de crecimiento de los beneficios

-2.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.6%
Tasa de crecimiento de los ingresos	13.1%
Rentabilidad financiera futura	15.1%
Cobertura de analistas	Low
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:AIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2025	1,488	262	N/A	446	2
3/31/2024	1,265	226	N/A	360	3
3/31/2023	1,144	269	N/A	299	3
9/30/2022	1,074	267	217	251	N/A
6/30/2022	1,056	218	263	298	N/A
3/31/2022	1,032	137	250	285	N/A
12/31/2021	1,003	133	246	293	N/A
9/30/2021	974	149	233	282	N/A
6/30/2021	935	154	248	298	N/A
3/31/2021	848	226	221	275	N/A
12/31/2020	813	200	237	275	N/A
9/30/2020	803	208	246	285	N/A
6/30/2020	798	159	240	282	N/A
3/31/2020	841	203	271	315	N/A
12/31/2019	841	245	257	299	N/A
9/30/2019	820	221	243	284	N/A
6/30/2019	797	258	229	270	N/A
3/31/2019	769	259	208	252	N/A
12/31/2018	737	222	191	238	N/A
9/30/2018	690	190	155	220	N/A
6/30/2018	641	165	142	203	N/A
3/31/2018	594	112	137	193	N/A
12/31/2017	544	90	103	173	N/A
9/30/2017	505	92	93	151	N/A
6/30/2017	475	77	70	125	N/A
3/31/2017	445	52	65	115	N/A
12/31/2016	415	48	69	100	N/A
9/30/2016	386	43	69	92	N/A
6/30/2016	359	42	N/A	92	N/A
3/31/2016	330	38	N/A	77	N/A
12/31/2015	303	126	N/A	73	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: AIO's earnings are forecast to decline over the next 3 years (-2.5% per year).

Beneficios vs. Mercado: AIO's earnings are forecast to decline over the next 3 years (-2.5% per year).

Beneficios de alto crecimiento: AIO's earnings are forecast to decline over the next 3 years.

Ingresos vs. Mercado: AIO's revenue (13.1% per year) is forecast to grow faster than the German market (3.5% per year).

Ingresos de alto crecimiento: AIO's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: AIO's Return on Equity is forecast to be low in 3 years time (15.1%).

This company listing is no longer active

Abiomed Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold €1.0m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) acquired all the assets and business from Sensera, Inc. for $7.5 million on January 4, 2022.

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold €4.5m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: €310

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: €267

New 90-day low: €216

Second quarter 2021 earnings released: EPS US$1.38

Revenue beats expectations

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

New 90-day high - €263

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento